Academic: Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria
EFPIA: Nicole Mahoney, MSD
Partners: L.J.V. Piddock, N. Brown T. Guise, V. Wells (British Society of Antimicrobial Chemotherapy), C. Clift, D. Heymann, E. Ross (Chatham House, London)
The private partners in DRIVE-AB are: AstraZeneca AB, GlaxoSmithKline Research & Development, F. Hoffmann-La Roche Ltd, MSD, Astellas Pharma Europe LTD, Pfizer Limited and Sanofi-Aventis Research & Development
- Identify and engage stakeholders through the development of a broad multidisciplinary stakeholder platform
- Develop and implement a comprehensive communication/engagement strategy that will involve and engage all stakeholders
- Establish effective relationships via meetings with and between decision makers central to the implementation of a new business model by engaging them early and throughout the project
- Communicate effectively the project’s findings and advances to the public
- Establish effective communication internally to ensure the communication flow between all WPs and stakeholders via WP3B
DOWNLOADS & RESOURCES
For more detail about Work Package 3B progress, please see our past NEWSLETTERS.
Posters and handouts
DRIVE-AB SME Stakeholder Meeting Report
Article: Development of new antibiotics: taking off finally?
Article: Recent FDA Antibiotic Approvals: Good News and Bad News
Article: Antibiotic research and development: business as usual?
If you would like to become a stakeholder, please REGISTER YOUR INTEREST with us to let us know exactly how you or your organization would like to engage with the project.
Click here for a list of current Associate Partners